Esthesioneuroblastoma: The Princess Margaret Hospital experience.
BACKGROUND
Esthesioneuroblastoma is rare. The aim of the study was to review our experience and to evaluate the staging system and treatment that best correlates with the patient outcome.


METHODS
Thirty-nine patients were identified between 1972 and 2006.


RESULTS
At presentation 10% had cervical metastases. None had distant metastasis. Five were treated with surgery, 2 with chemotherapy, 1 with radiotherapy, and 30 with surgery and radiation. Local disease control was 82.6% at 5 years. Recurrence was seen in 33% with local and regional disease recurrence at 15% and 18%, respectively. The 5- and 10-year overall survival rates were 87.9% and 69.2%, respectively. Dulguerov classification correlated most closely to survival and recurrence.


CONCLUSIONS
Dulguerov classification best correlates with the patient's outcome. A combined approach is the preferred treatment. It makes no difference whether radiotherapy is given pre or postsurgical resection. Recurrence can occur even 15 years after treatment. Therefore, long-term follow-up is essential.
Bachar
Gideon
G
Department of Otolaryngology-Head and Neck Surgery, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada.
Goldstein
David P
DP
Shah
Manish
M
Tandon
Asheesh
A
Ringash
Jolie
J
Pond
Gregory
G
Gullane
Patrick J
PJ
Perez-Ordonez
Bayardo
B
Gilbert
Ralph W
RW
Brown
Dale H
DH
Gentili
Fred
F
O'Sullivan
Brian
B
Irish
Jonathan C
JC
D000328:Adult; D000368:Aged; D018304:Esthesioneuroblastoma, Olfactory / Q000473:pathology / Q000628:therapy*; D005260:Female; D005500:Follow-Up Studies; D006785:Hospitals, University; D006801:Humans; D008297:Male; D008875:Middle Aged; D009296:Nasal Cavity; D037981:Neck Dissection; D009364:Neoplasm Recurrence, Local / Q000473:pathology / Q000628:therapy*; D009367:Neoplasm Staging; D009669:Nose Neoplasms / Q000473:pathology / Q000628:therapy*; D009864:Ontario; D012189:Retrospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome